Abstract 130P
Background
Neoadjuvant treatment of immune checkpoint inhibitors have shown a high pathologic complete response (pCR) rate in patients with dMMR/MSI-H, locally advanced colorectal cancer (LACRC). Cadonilimab (AK104), a novel bispecific antibody simultaneously targeting PD-1 and CTLA-4, was designed to boost anti-tumor activity with a favorable safety profile. Here, we primary reported the efficacy and safety of AK104 in the neoadjuvant treatment of dMMR/MSI-H LACRC, while concurrently exploring the potential for surgery avoidance.
Methods
The study was a multi-cohort, phase 2 trial, consisted of Cohort A (locally advanced colon cancer) and B (Locally Advanced Rectal Cancer). Patients (pts) with dMMR/MSI-H, LACRC were enrolled to receive AK104 (10mg/kg, iv, d1, q3w) for up to 8 cycles. The primary endpoint is the complete response rate (CR, pCR plus cCR). Secondary endpoints include MPR rate, R0 resection rate, DFS, OS, and safety.
Results
From April 2023 to August 2024, 34 pts were enrolled (26 in Cohort A and 8 in Cohort B). Baseline characteristics of pts are listed in the table. 34 pts had at least 2 cycles of treatment. In Cohort B, 4 pts completed the entire neoadjuvant treatment, and all reached the cCR. Currently, 13 pts (12 in Cohort A and 1 in Cohort B) received surgical resection, and the R0 resection rate was 100%. The pCR rate was 84.6% (11/13) and the MPR rate was 100 % (13/13). The median DFS was not reached. Treatment-related adverse events (TRAEs) occurred in 18/34(53%) pts. 5 /34 (14.7%) pts experienced grade 3-4 treatment-related adverse events (TRAEs), which included adrenocortical hypofunction (1 pt), myocarditis (1 pt), myositis (2 pts), and thrombocytopenia (1pt). No grade 5 AEs were observed. Table: 130P
| Characteristics | Cohort A, N=26 | Cohort B, N=8 |
| Age (years, median range) | 52 (18, 73) | 55 (48,68) |
| Gender | ||
| Female | 11 (42) | 1 (13) |
| Male | 15 (58) | 7 (87) |
| ECOG PS | ||
| 0 | 18 (69) | 6 (75) |
| 1 | 8 (31) | 2 (25) |
| Clinical T category | ||
| cT3 | 6 (23) | 5 (62) |
| cT4a | 20 (77) | 3 (38) |
| Clinical N category | ||
| N+ | 26 (100) | 7 (88) |
| N0 | 0 (0) | 1 (12) |
Conclusions
Cadonilimab showed promising efficacy with an outstanding pCR rate and manageable safety profile in locally advanced dMMR/MSI-H colorectal cancer patients. This trial is still ongoing and needs long-term follow-up.
Clinical trial identification
NCT05815290.
Legal entity responsible for the study
The authors.
Funding
Akeso Biopharma.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
135P - Efficacy and safety of tislelizumab combined with bronchial arterial infusion (BAI) chemotherapy in potentially resectable stage IIIB non-small cell lung cancer(NSCLC): A prospective, single-arm phase II clinical study
Presenter: Xu Ma
Session: Poster Display session
Resources:
Abstract
136P - Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous NSCLC (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy: An updated analysis
Presenter: Baohui Han
Session: Poster Display session
Resources:
Abstract
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
Resources:
Abstract
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
Resources:
Abstract
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
Resources:
Abstract
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
Resources:
Abstract
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
Resources:
Abstract
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
Resources:
Abstract
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract